Lastres-Becker I - Search Results

1

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J. Sagredo O, et al. Glia. 2009 Aug 15;57(11):1154-67. doi: 10.1002/glia.20838. Glia. 2009. PMID: 19115380 Free PMC article.

2

Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide.

González S, Romero J, de Miguel R, Lastres-Becker I, Villanua MA, Makriyannis A, Ramos JA, Fernández-Ruiz JJ. González S, et al. Life Sci. 1999;65(3):327-36. doi: 10.1016/s0024-3205(99)00251-9. Life Sci. 1999. PMID: 10447218

3

Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.

Lastres-Becker I, Fezza F, Cebeira M, Bisogno T, Ramos JA, Milone A, Fernández-Ruiz J, Di Marzo V. Lastres-Becker I, et al. Neuroreport. 2001 Jul 20;12(10):2125-9. doi: 10.1097/00001756-200107200-00017. Neuroreport. 2001. PMID: 11447320

4

Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration.

Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikonomidou C, Schmid HH, Fernández-Ruiz JJ, Hansen HS. Hansen HH, et al. J Neurochem. 2001 Sep;78(6):1415-27. doi: 10.1046/j.1471-4159.2001.00542.x. J Neurochem. 2001. PMID: 11579150 Free article.

5

Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.

López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, Lastres-Becker I, González S, Fernández-Ruiz J, Ramos JA. López-Rodríguez ML, et al. J Med Chem. 2001 Dec 20;44(26):4505-8. doi: 10.1021/jm015545y. J Med Chem. 2001. PMID: 11741470

6

Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.

Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Pérez-Rosado A, Manzanares J, Ramos JA, Fernández-Ruiz J. Lastres-Becker I, et al. Synapse. 2002 Apr;44(1):23-35. doi: 10.1002/syn.10054. Synapse. 2002. PMID: 11842443

7

Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.

Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernández-Ruiz JJ. Lastres-Becker I, et al. Eur J Neurosci. 2001 Dec;14(11):1827-32. doi: 10.1046/j.0953-816x.2001.01812.x. Eur J Neurosci. 2001. PMID: 11860478

8

Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.

Lastres-Becker I, Berrendero F, Lucas JJ, Martín-Aparicio E, Yamamoto A, Ramos JA, Fernández-Ruiz JJ. Lastres-Becker I, et al. Brain Res. 2002 Mar 8;929(2):236-42. doi: 10.1016/s0006-8993(01)03403-5. Brain Res. 2002. PMID: 11864629

9

Endocannabinoids and basal ganglia functionality.

Fernández-Ruiz J, Lastres-Becker I, Cabranes A, González S, Ramos JA. Fernández-Ruiz J, et al. Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):257-67. doi: 10.1054/plef.2001.0350. Prostaglandins Leukot Essent Fatty Acids. 2002. PMID: 12052041 Review.

10

The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.

Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernández-Ruiz J. Romero J, et al. Pharmacol Ther. 2002 Aug;95(2):137-52. doi: 10.1016/s0163-7258(02)00253-x. Pharmacol Ther. 2002. PMID: 12182961 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters